FDA II-63
Morphotek Grants FDA Approval of the IND for MORAb-009 II-63
MannKind Receives IND Clearance for MKC1106-PP Immunotherapy II-63
Pharmexa Initiates Phase II trials of GV 1001 II-64
Wyeth Pharmaceuticals Declares Discontinuation of Phase III
Clinical Trials for Temsirolimus II-64
OXiGENE Announces Clinical Trials of CA4P II-64
Glaxo Smith Kline's Hycamtin Gains FDA Approval for Treating
Cervical Cancer II-64
Cell Genesys Announces the Initiation of Amplified Phase I
Trial of CG0070 II-65
Genentech's Avastin Receives FDA Approval for Lung Cancer
Treatment II-65
Vorinostat Acquires FDA Approval for Skin Cancer Treatment II-65
Callisto Launches the First Clinical Trial of Landmark
Discovery, L-Annamycin for ALL II-65
Shanghai Sunway Biotech's H101 Receives Marketing Approval in
China II-66
Northwest Biotherapeutics Gains Patent for CXCR4 II-66
Biocon's Cancer Drug Initiates Phase II Trials II-67
4. New Drug Developments and Launches II-68
GSK Launches Cervarix in Singapore II-68
Abeome Launches New Stem Cell Monoclonal Antibody II-68
Dabur Pharma Launches a New Drug Delivery System, Nanoxel II-68
Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs II-68
Monash University Scientists Develop siRNA for Cancer Treatment II-69
Cytogen Introduces SOLTAMOX(TM), the First Hormonal Breast
Cancer Therapy II-69
5. Recent Industry Activity II-70
Avexa to Acquire Progen Pharmaceuticals II-70
Abraxis Takes Over Platco and Shimoda II-70
WEHI Collaborates with Abbott and Genentech II-70
Novartis Inks a Production Deal with Lonza II-70
Roche to Take Over UK-Based Biotech Company, Piramed II-71
Pfizer Acquires Encysive II-71
Ede
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |